

References :

1. **Cazzola M. (1994):** Problems and prospectives in the antibiotic treatment of lower respiratory tract infection. *Pulm .Pharma*; 7: 139-152 .
2. **Barry AL., and Brown (1996):** Reconsideration of the interpretive criteria for larithromycin against *Hemophilus influenza* . *Antimicrob agents chemother* ; 39 : 221-226 .
3. **Frere JM. (1995) :** Beta lactamase and bacterial resistance to antibiotic . *Mol. Microbial* ; 16 : 385-395 .
4. **Davey PG. (2000):** "Antimicrobial chemotherapy". in Ledingham JGG, Warrell DA. *Concise Oxford Textbook of Medicine*. Oxford: Oxford University Press; pp. 1475.
5. **Richard A. Harvey, and Pamela C. Champe (2008):** Pharmacology, Principles of antimicrobial therapy. Lippincott's illustrated Reviews, 4th. Edition ; 7 (30): 347-358.
6. **Kox, L. F. F., J. van Leeuwen, S. Knijper [sic], H. M. Jansen, and A. H. J Kolk (1995):** PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. *J. Clin. Microbiol*; 33: 3225-3233.
7. **Montessori, V., P. Phillips, J. Montaner, L. Italey, K. Craib, E. Besuille, and W. Black (1996):** Species distribution in human immunodeficiency virus-related mycobacterial infections: implications for selection of initial treatment. *Clin. Infect. Dis*; 22:989–992.
8. **Anonymous (1999):** The choice of antibacterial drugs. *Drugs of choice, by clinical situation and organism. Med Letter*; 41: 95-104.
9. **Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC (2001):** What do we really know about antibiotic pharmacodynamics? *Pharmacotherapy*; 21(11 Pt 2):302S-318S.
10. **Leibovici L., Shraga I., and Andreassen S. (1999):** How do you choose an antibiotic regime? *BMJ. Jun 12*;318(7198):1614-6.
11. **Cazzola M., Diamare F., Vinciguerra A., Salzillo A., and Calderaro F. (1996):** Pulmonary penetration of antibiotics and its clinical impact [La penetrazione polmonare degli antibiotici e il suo impatto clinico]. *Rass Pat App Respir*; 11: 134-147.
12. **Honeybourne D. (1997):** Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. *Curr Opin Pulm Med*; 3: 170-174.
13. **Warren P. (1997):** Antibiotics Are They Wonder Drugs? the principles that doctors should follow in prescribing antibiotics.
14. **Glenn M., Joshua Lee, Gilad J., et al. (2001):** Guided Medication Dosing for Inpatients With Renal Insufficiency.
15. **Ramón Azanza J., García E., Sádaba B., and Manubens A. (2009):** [Antibiotic use in patients with renal or hepatic failure]. *Enferm Infec Microbiol Clin*; 27(10):593-9.
16. **Macy E., and Poon K-Y T. (2009):** Self-reported antibiotic allergy incidence and prevalence: age and sex effects. *Am J Med*;122(8):778.e1-7.
17. **Sabah Saad Oraby (2008):** Antibiotics and Pregnancy. In, *Egyptian Pneumology Guide Book. (7)*: 46-50.
18. **Rodney L. Thompson, and Alan J. Wright (1998):** Symposium on antimicrobial agents. General principles of antimicrobial therapy. *Mayo Clinic Proceedings*; 73, 10; ProQuest Medical Library pg. 995.
19. **Kuhn RJ (2001):** Formulation of aerosolized therapeutics. *Chest*; 120:94-98.

20. **Zhanel GG, Walters M, Laing N, and Hoban DJ (2001):** In vitro pharmacodynamic modeling simulating free serum concentrations of fluoroquinolones against multidrug-resistant *Streptococcus pneumoniae*. *J Antimicrob Chemother*; 47: 435-440.
21. **Craig W. (1993):** Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. *Eur J Clin Microbiol Infect Dis*; 12:Suppl 1: S6-8.
22. **Guan L., Blumenthal RM, and Burnham JC (1992):** "Analysis of macromolecular biosynthesis to define the quinolone-induced postantibiotic effect in *Escherichia coli*". *Antimicrob. Agents Chemother*; 36 (10): 2118-24.
23. **Abed Athamna, Muhammad Athamna, Aburashed Nura, et al. (2005):** Is In Vitro Antibiotic Combination More Effective than Single-Drug Therapy against Anthrax? *Antimicrob. Agents Chemother*; 49(4): 1323-1325.
24. **Laurence L. Brunton, Louis Sanford Goodman, Donald Blumenthal, and Iain Buxton (2007):** Goodman and Gilman's manual of pharmacology and therapeutics; Pg.712.
25. **Anderson JA (1992):** Allergic reactions to drugs and biological agents. *JAMA*; 268: 2845-2858.
26. **WHO Global Strategy for Containment of Antimicrobial Resistance (2001):** Drug resistance.
27. **Christine Cadena (2007):** Antibiotic-Induced Colitis: Secondary Complication of Antibiotic Usage. Symptoms and Treatment.
28. **Hagerman JK, Hancock KE, and Klepser ME (2006):** Aerosolised antibiotics: a critical appraisal of their use. *Expert Opin. Drug Deliv*; 3(1): 71-85.
29. **H.F and Sande, M.A. (1996):** Antimicrobial Agents. In, Goodman and Gillman's The Pharmacological Basis of Therapeutics, (Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc; pp.1029-1030.
30. **Mascio CT, Alder JD, and Silverman JA (2007):** "Bactericidal action of daptomycin against stationary-phase and nondividing *Staphylococcus aureus* cells". *Antimicrob. Agents Chemother*; 51 (12): 4255-60.
31. **Rosen P., Barkin RM, eds (1992):** Emergency Medicine: Concepts and Clinical Practice. Mosby-Year Book.
32. **Mona A. Osman (2008):** Chemotherapeutic Drugs. In, Egyptian Pneumology Guide Book; (6): 35-45.
33. **Holten KB, and Onusko EM (2000):** "Appropriate prescribing of oral beta-lactam antibiotics". *American family physician*; 62 (3): 611-20.
34. **Henry F. Chambers, and Daniel H. Deck (2009):** Beta-lactam and other cell wall and membrane active antibiotics. In (Bertram G. Katzung. Basic and Clinical Pharmacology). 11ed. McGraw-Hill Medical; 8 (43): 773-793.
35. **Richard A. Harvey, and Pamela C. Champe (2008):** Pharmacology, Cell wall inhibitors. Lippincott's illustrated Reviews, 4th. Edition; 7 (31): 359-372.
36. **U.S. National Library of Medicine, Daily Med. (2006):** "Penicillin V Potassium tablet: Drug Label Sections" Current Medication Information.
37. **Rossi S. (2006):** Australian Medicines Handbook. Adelaide: Australian Medicines Handbook.
38. **United States Food & Drug Administration (2007):** "FDA Strengthens Labels of Two Specific Types of Antibiotics to Ensure Proper Use."
39. **M.A.Abd El Hamid (1998):** Pharmacology. "Chemotherapy" ;Vol (2) : 236-252.

40. **Douglas Seaton (2001):** "Drugs in lung disease". In, Crofton and Douglas's Respiratory Diseases, (Anthony Seaton, Douglas Seaton, and The late A. Gordan Leitch). 5th Edition; (9):193-310.
41. **Salkind AR, Cuddy PG, Foxworth JW (2001):** "Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy". JAMA; 285 (19): 2498-505.
42. **Solensky R (2003):** "Hypersensitivity reactions to beta-lactam antibiotics". Clinical reviews in allergy & immunology; 24 (3): 201–20.
43. **Gruchalla RS, Pirmohamed M (2006):** "Clinical practice. Antibiotic allergy". N. Engl. J. Med; 354 (6): 601-9.
44. **Pichichero ME (2007):** "Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift". Diagn. Microbiol. Infect. Dis; 57 (3 Suppl): 13S-8S.
45. **Dorland's Medical Dictionary (2010):** 31st Ed. Cephalosporin.
46. **British National Formulary (2008):** (56 ed.). "5.1.2 Cephalosporins and other beta-lactams" London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society Publishing. September; pp. 295.
47. **Karchmer AW. (1995):** Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone.
48. **Mandell GL and Petri WA (1996):** Antimicrobial Agents: Penicillins, Cephalosporins, and other β -Lactam Antibiotics. In, Goodman and Gillman's The Pharmacological Basis of Therapeutics, (Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R. W. and Gilman, A. G., eds) The McGraw-Hill Companies, Inc.; pp.1089-1092.
49. **Mark H. Beers, et al., eds. (2003):** The Merck Manual of Medical Information. 2nd Home Edition. Whitehouse Station, NJ: Merck.
50. **Stork CM (2006):** "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.). Goldfrank's toxicologic emergencies. New York: McGraw-Hill; pp. 847.
51. **British National Formulary, no.37 (1999):** Wallingford: Pharmaceutical Press.
52. **Phillips I., and Shannon K. (1993):** "Importance of beta-lactamase induction". Eur J Clin Microbiol Infect Dis; 12 Suppl 1: S19–26.
53. **Barclay, and Laurie (2007):** "CDC issues new treatment recommendations for gonorrhea". Medscape.
54. **Gilbert DN, Moellering RC, Eliopoulos GM, et al, eds. (2007):** The Sanford Guide To Antimicrobial Therapy, 37th ed, Sperryville, VA: Antimicrobial Therapy, Inc; 170.
55. **Trotman RL, Williamson JC, Shoemaker DM, et al. (2005):** "Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy," Clin Infect Dis; 41(8):1159-66.
56. **Yahav D., Paul M., Fraser A., Sarid N., and Leibovici L. (2007):** "Efficacy and safety of cefepime: a systematic review and meta-analysis". Lancet Infect Dis; 7 (5): 338–48.
57. **Chapman TM, and Perry CM (2003):** "Cefepime: a review of its use in the management of hospitalized patients with pneumonia". Am J Respir Med; 2 (1): 75–107.
58. **"Information for Healthcare Professionals (2009):** Cefepime (marketed as Maxipime)".
59. **Widmer AF (2008):** "Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*". Clin.infect. Dis; 46 (5): 656–8.

60. **Kosinski MA, and Joseph WS (2007):** "Update on the treatment of diabetic foot infections". Clin Podiatr Med; Surg 24 (3): 383-96, vii.
61. **Walkty A, DeCorby M, Nichol K, et al. (2008):** In vitro activity of ceftobiprole against clinical isolates of *Pseudomonas aeruginosa* obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. J Antimicrob Chemother; 62 (1): 206-208.
62. **Jones ME (2007):** In vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant *Staphylococcus aureus*. Clin Microbiol Infect; 13(Suppl 2): 17-24.
63. **Pillar CM, Aranza MK, Shah D, et al. (2008):** In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother; 61(3): 595-602.
64. **Pegler S, and Healy B. (2007):** "In patients allergic to penicillin, consider second and third generation cephalosporins for life threatening infections".
65. **Pichichero ME (2006):** "Cephalosporins can be prescribed safely for penicillin-allergic patients" (PDF). The Journal of family practice; 55 (2): 106-12.
66. **Shearer MJ, Bechtold H, Andrassy K, et al. (1988):** "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status". Journal of clinical pharmacology; 28 (1): 88–95.
67. **Stork CM (2006):** "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA. Goldfrank's toxicologic emergencies. New York: McGraw-Hill; pp. 847.
68. **Mainardi JL, Villet R, Bugg TD, Mayer C, and Arthur M. (2008):** "Evolution of peptidoglycan biosynthesis under the selective pressure of antibiotics in Gram-positive bacteria". FEMS Microbiol Rev; 32 (2): 386–408.
69. **Jill E. Maddison, and Stephen W. (2008):** Page, David Church. Small animal clinical pharmacology; pp.168.
70. **Birnbaum J, Kahan FM, Kropp H, and MacDonald JS. (1985):** "Carbapenems, a new class of beta- lactam antibiotics. Discovery and development of imipenem/cilastatin". Am. J. Med; 78 (6A): 3-21.
71. **Bilgrami I, Roberts J. A, Wallis S. C, Thomas J, et al. (2010):** "Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High Volume Continuous Veno-Venous Hemofiltration". Antimicrobial Agents and Chemotherapy; 54 (7): 2974.
72. **Livermore DM, Mushtaq S., and Warner M. (2005):** "Selectivity of ertapenem for *Pseudomonas aeruginosa* mutants cross-resistant to other carbapenems". J Antimicrob Chemother; 55 (3): 306–311.
73. **AHFS DRUG INFORMATION (2006):** American Society of Health-System Pharmacists.
74. **U.S. Food and Drug Administration (2007):** "FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections". Press release.
75. **Center for Disease Control and Prevention (2010):** "Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States". Morbidity and Mortality Weekly Report; 59 (24): 750.
76. **Livermore DM, and Woodford N. (2000):** "Carbapenemases: a problem in waiting?". Current Opinion in Microbiology; 3 (5): 489–95.
77. **European Medicines Agency. (2008):** "CHMP Assessment Report for Doribax".

78. **Kumagai T., Tamai S., Abe T., and Hikda M. (2002):** "Current status of oral carbapenem development". *Current Medicinal Chemistry - Anti-Infective Agents*; 1 (1): 1–14.
79. **Margolin L. (2004):** Impaired rehabilitation secondary to muscle weakness induced by meropenem. *Clin. Drug Invest*; 24(1):61-2.
80. **R. Bharti, S. Gombar, and AK Khanna. (2010):** Meropenem in critical care - uncovering the truths behind weaning failure. *J Anaesth Clin Pharmacol*; 26(1): 99-101.
81. **Mosby's Drug Consult. (2006):** (16 ed ed.). Mosby, Inc.
82. **Larkin, and Catherine (2010):** "Gilead's Inhaled Antibiotic for Lungs Wins Approval". *BusinessWeek*.
83. **British National Formulary. (2007):** (54 ed.).
84. **"Augmentin -- Prescribing Information" (PDF). (2006):** GlaxoSmithKline.
85. **Davies BE, Boon R, Horton R, Reubi FC, and Descoeudres CE (1988):** "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin". *Br J Clin Pharmacol*; 26 (4): 385–90.
86. **Paul A. and John G. (2010):** Ticarcillin + Clavulanic Acid. www.rxlist.com/timentin-drug.htm.
87. **CAPT Michael John Hughey, MC, USNR. (2001):** Ampicillin with sulbactam (unisyn). *Operational Medicine 2001. Health Care in Military Settings. NAVMED*; P-5139.
88. **The clinician's ultimate reference (2007):** Global RPh. com. piperacillin/tazobactam.
89. **Loffler CA, and Macdougall C. (2007):** Update on prevalence and treatment of methicillin-resistant *Staphylococcus aureus* infections, *Expert Rev Anti Infect Ther*; 5(6):961-81.
90. **Van Bambeke F. (2006):** Glycopeptides and glycopeptide antibiotics in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy, *Curr Opin Investig Drugs*; 7(8):740-9.
91. **Shnayerson, Michael; Plotkin, Mark (2003):** *The Killers Within: The Deadly Rise of Drug-Resistant Bacteria*. Back Bay Books.
92. **Samel SA, Marahiel MA, and Essen LO (2008):** "How to tailor non-ribosomal peptide products-new clues about the structures and mechanisms of modifying enzymes". *Mol Biosyst*; 4 (5): 387–93.
93. **Matzke GR, Zhanel GG, and Guay DR (1986):** Clinical pharmacokinetics of vancomycin. *Clin Pharmacokinet*; 11(4):257-82.
94. **Small PM, and Chambers HF (1990):** "Vancomycin for *Staphylococcus aureus* endocarditis in intravenous drug users". *Antimicrob Agents Chemother*; 34 (6): 1227–31.
95. **Gonzalez C., Rubio M., et al. (1999):** "Bacteremic pneumonia due to *Staphylococcus aureus*: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms". *Clin Infect Dis*; 29 (5): 1171–7.
96. **Cantú TG, Yamanaka-Yuen NA, and Lietman PS (1994):** "Serum vancomycin concentrations: reappraisal of their clinical value". *Clin Infect Dis*; 18 (4): 533–43.
97. **Lodise TP, Patel N, Lomaestro BM, Rodvold KA, and Drusano GL (2009):** "Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients". *Clin Infect Dis*; 49 (4): 507–514.
98. **Farber BF, and Moellering RC Jr (1983):** "Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.". *Antimicrob Agents Chemother*; 23 (1): 138.

99. **Drygalski A., and Curtis BR (2007):** "Vancomycin-Induced Immune Thrombocytopenia". *N Engl J Med*; 356 (9): 904.
100. **Weston B., Wahab N., Roberts T., and Mason R. (2001):** "Bacitracin inhibits fibronectin matrix assembly by mesangial cells in high glucose". *Kidney international*; 60 (5): 1756–1764.
101. **Karala AR, and Ruddock LW (2010):** "Bacitracin is not a specific inhibitor of protein disulfide isomerase". *FEBS Journal*; 277: 2454.
102. **Discover Magazine (2007):** Antibiotic use on the farm hurts people and doesn't help the bottom line.
103. **Grif K., Dierich MP, Pfaller K., Miglioli PA, and Allerberger F. (2001):** "In vitro activity of fosfomycin in combination with various antistaphylococcal substances". *The Journal of antimicrobial chemotherapy*; 48 (2): 209–17.
104. **Brown ED, Vivas EI, Walsh CT, and Kolter R. (1995):** "MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in *Escherichia coli*". *J. Bacteriol*; 177 (14): 4194–7.
105. **Patel SS, Balfour JA, and Bryson HM. (1997):** "Fosfomycin tromethamine: A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections". *Drugs*; 53 (4): 637–656.
106. **Falagas ME, Giannopoulou KP, Kokolakis GN, and Rafailidis PI. (2008):** "Fosfomycin: use beyond urinary tract and gastrointestinal infections". *Clin. Infect. Dis*; 46 (7): 1069–77.
107. **Falagas ME, Grammatikos AP, and Michalopoulos A. (2008):** Potential of old-generation antibiotics to address current need for new antibiotics. *Expert Rev Anti Infect Ther*; 6(5):593-600.
108. **Rigsby R., Fillgrove K., Beihoffer L., and Armstrong R. (2005):** "Fosfomycin Resistance Proteins: A Nexus of Glutathione Transferases and Epoxide Hydrolases in a Metalloenzyme Superfamily". *Methods in Enzymology*; 401: 367.
109. **www. netdoctor.co.uk/infections. (2004):** " Cycloserine". How does it work? ORAL (Seromycin) side- CYCLOSERINE.
110. **Miao V, Coëffet-Legal MF, and Brian P. (2005):** "Daptomycin biosynthesis in *Streptomyces roseosporus*: cloning and analysis of the gene cluster and revision of peptide stereochemistry". *Microbiology (Reading, Engl.)*; 151 (Pt 5): 1507–23.
111. **Greenwood Village (CO): Thomson Micromedex (2006):** Daptomycin. In: Klasco RK, editor. *Drugdex system*; vol. 129.
112. **Richard A. Harvey, and Pamela C. Champe. (2008):** Pharmacology, Protein synthesis inhibitors. *Lippincott's illustrated Reviews*, 4th. Edition; 7 (32): 373-386.
113. **Office of Public Health (2010):** Call the Infectious Disease Epidemiology Section, Louisiana Department of Health and Hospitals; (504-219-4563).
114. **The "Gold Book" (1997). Online corrected version. (2006):** "tetracyclines". *IUPAC, Compendium of Chemical Terminology*, 2nd ed.
115. **Henry F. Chambers, and Daniel H. Deck (2009):** Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, & Oxazolidinones. In (Bertram G. Katzung. *Basic and Clinical Pharmacology*). 11ed. McGraw-Hill Medical; 8 (44): 795-806.

116. **Cunha BA, Comer JB, and Jonas M. (1982):** The tetracyclines. *Med Clin North Am*; 66: 293.
117. **Sherwood L. Gorbach, John G. Bartlett, and Neil R. (2004):** Classification of tetracyclines. Blacklow. *Infectious diseases*. 3rd. edition; pp.209.
118. **Olson MW, Ruzin A., Feyfant E., Rush TS, O'Connell J., and Bradford PA (2006):** "Functional, biophysical, and structural bases for antibacterial activity of tigecycline". *Antimicrobial agents and chemotherapy*; 50 (6): 2156–66.
119. **Livermore DM (2005):** "Tigecycline: what is it, and where should it be used?". *J. Antimicrob. Chemother*; 56 (4): 611–4.
120. **Smith KL, McCabe SM, and Aeschlimann JR (2005):** "Tigecycline: A novel glycylcycline antiobiotic". *Formulary*.
121. **Massachusetts Institute of Technology (2008):** "Bacterial 'Battle For Survival' Leads To New Antibiotic."
122. **J Biomed Sci. (2008):** Aminoglycosides versus bacteria--a description of the action, resistance mechanism, and nosocomial battleground; 15(1):5-14.
123. **Champney WS (2001):** "Bacterial ribosomal subunit synthesis: a novel antibiotic target". *Curr Drug Targets Infect Disord*; 1 (1): 19–36.
124. **Lorian, and Victor (1996):** "Antibiotics in Laboratory Medicine". Williams & Wilkins Press; (pp. 589-590).
125. **Falagas ME, Grammatikos AP, and Michalopoulos A. (2008):** Potential of old-generation antibiotics to address current need for new antibiotics. *Expert Rev Anti Infect Ther*; 6(5):593-600.
126. **Henry F. Chambers, Daniel H. Deck (2009):** Aminoglycosides & Spectinomycin. In (Bertram G. Katzung. *Basic and Clinical Pharmacology*). 11ed. McGraw-Hill Medical; 8 (45): 807-814.
127. **Gilbert DN (1995):** Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases*. New York: Churchill Livingstone.
128. **Durante-Mangoni E., Grammatikos A., Utili R., and Falagas ME. (2009):** Do we still need the aminoglycosides? *Int J Antimicrob Agents*; 33(3):201-5.
129. **Wilschanski M., Yahav Y., Yaacov Y., et al. (2003):** "Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations". *N. Engl. J. Med*; 349 (15): 1433–41.
130. **Smith AL, and Ramsey B. (1995):** Aerosol Administration of antibiotics. *Respiration*; 62 (Suppl 1): 19.
131. **"From the Centers for Disease Control and Prevention. Update on spectinomycin availability in the United States". (2001):** *JAMA*; 286 (11): 1308–9.
132. **Kehrenberg C., and Schwarz S. (2007):** "Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in *Pasteurella multocida*". *Antimicrob. Agents Chemother*; 51 (6): 2244–6.
133. **The Community College of Baltimore County (2009):** Protein synthesis inhibitors: macrolides mechanism of action animation. Classification of agents Pharmamotion. Author: Gary Kaiser.
134. **Keicho N., and Kudoh S. (2002):** "Diffuse panbronchiolitis: role of macrolides in therapy". *Am J Respir Med*; 1 (2): 119–131.

135. **Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. (2004):** Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes. *N Engl J Med*; 351:1089-96.
136. **Dunn CJ , and Barradell LB. (1996):** Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. *Drugs*; 51: 438.
137. **Schentag JJ, and Ballow CH (1991):** Tissue directed pharmacokinetics. *Am J Med*; 91(Suppl 3a): 5s.
138. **Pfizer Inc, New York, NY. (2008):** Zmax® (azithromycin extended release) for oral suspension, Prescribing Information.
139. **Drehobl MA, De Salvo MC, Lewis DE, and Breen JD (2005):** Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. *Chest*; 128: 2230-2237.
140. **Sathasivam, Sivakumar, and Lecky B. (2008):** "Statin induced myopathy". *British Medical Journal*; 337: a2286.
141. **Fraser KL, and Grossman RF. (1998):** What new antibiotics to offer in the outpatient setting. *Semin Respir Infect*; 13: 24.
142. **Scheinfeld N. (2004):** Telithromycin: A brief review of a new ketolide antibiotic. *J Drug Dermat*; 3: 409-13.
143. **Harold M. (2006):** Silverman, Pharm.D. (editor-in-chief), ed. "Iron Supplements". *Pill Book, The* (12th revised ed. ed.). New York: Bantam Dell; pp. 593–596.
144. **McIntyre J., and Choonara I. (2004):** "Drug toxicity in the neonate.". *Biol Neonate*; 86 (4): 218–21.
145. **Park JY, Kim KA, and Kim SL (2003):** "Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes". *Antimicrob. Agents Chemother*; 47 (11): 3464–9.
146. **Daum RS (2007):** "Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant *Staphylococcus aureus*". *N Engl J Med*; 357 (4): 380–90.
147. **Brook I., Lewis MA, et al. (2005):** Clindamycin in dentistry: more than just effective prophylaxis for endocarditis? *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* ;100:550-8.
148. **Darley ES, and MacGowan AP (2004):** "Antibiotic treatment of gram-positive bone and joint infections". *J Antimicrob Chemother*; 53 (6): 928–35.
149. **Feldman S., Careccia RE, Barham KL, and Hancox J. (2004):** "Diagnosis and treatment of acne". *Am Fam Physician*; 69 (9): 2123–30.
150. **Thomas C, Stevenson M, and Riley TV (2003):** "Antibiotics and hospital-acquired *Clostridium difficile*-associated diarrhoea: a systematic review". *J Antimicrob Chemother*; 51 (6): 1339–50.
151. **Starr J. (2005):** "Clostridium difficile associated diarrhoea: diagnosis and treatment". *BMJ*; 331 (7515): 498–501.
152. **Allington DR, and Rivey MP (2001):** "Quinupristin/dalfopristin: a therapeutic review.". *Clin Ther*; 23(1):24-44.
153. **Tascini C., Gemignani G., Doria R., et al. (2009):** "Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin". *Journal of Chemotherapy (Florence, Italy)*; 21 (3): 311–6.

154. **Ament PW, Jamshed N., and Horne JP (2002):** "Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections". *American Family Physician*; 65 (4): 663–70.
155. **Herrmann DJ, Peppard WJ, et al. (2008):** "Linezolid for the treatment of drug-resistant infections". *Expert Review of Anti-infective Therapy*; 6 (6): 825–48.
156. **Barbachyn MR, and Ford CW (2003):** "Oxazolidinone structure-activity relationships leading to linezolid". *Angewandte Chemie (International Edition in English)*; 42 (18): 2010–23.
157. **Sisson TL, Jungbluth GL, and Hopkins NK (2002):** "Age and sex effects on the pharmacokinetics of linezolid". *European Journal of Clinical Pharmacology*; 57(11): 793–7.
158. **Lexi-Comp (2008):** "Linezolid". *The Merck Manual Professional*. Retrieved on May 14, 2009.
159. **Grau S., and Rubio-Terrés C. (2008):** "Pharmacoeconomics of linezolid". *Expert Opinion on Pharmacotherapy*; 9 (6): 987–1000.
160. **Nelson JM, Chiller TM, Powers JH, and Angulo FJ (2007):** "Fluoroquinolone-resistant *Campylobacter* species and the withdrawal of fluoroquinolones from use in poultry: a public health success story". *Clin. Infect. Dis*; 44 (7): 977–80.
161. **Muto CA, Jernigan JA, et al (2003):** "SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of *Staphylococcus aureus* and enterococcus". *Infect Control Hosp Epidemiol*; 24 (5): 362–86.
162. **Hooper DC (2001):** "Emerging mechanisms of fluoroquinolone resistance." (PDF). *Emerg Infect Dis*; 7 (2): 337–41.
163. **Bergan T. Bayer (1988):** "Pharmacokinetics of fluorinated quinolones". *Academic Press*; 119–154.
164. **Henry F. Chambers, and Daniel H. Deck (2009):** Sulfonamides, Trimethoprim and Quinolones. In (Bertram G. Katzung. *Basic and Clinical Pharmacology*). 11ed. McGraw-Hill Medical; 8 (46): 815–822.
165. **Ball P. (2000):** "Quinolone generations: natural history or natural selection?". *J. Antimicrob. Chemother*; 46 Suppl T1 (Supplement 3): 17–24.
166. **American Academy of Family Physicians (2008):** "New Classification and Update on the Quinolone Antibiotics. "
167. **American Family Physician (2006):** "Quinolones: A Comprehensive Review".
168. **Oliphant CM, and Green GM (2002):** "Quinolones: a comprehensive review". *Am Fam Physician* 65 (3): 455–64.
169. **Richard A. Harvey, and Pamela C. Champe (2008):** Pharmacology, Quinolones, Folic acid antagonists, and Urinary tract antiseptics. *Lippincott's illustrated Reviews*, 4th. Edition; 7 (33): 387–398.
170. **Bayer HealthCare Pharmaceuticals (2009):** "CIPRO (ciprofloxacin hydrochloride) TABLETS CIPRO (ciprofloxacin*) ORAL SUSPENSION".
171. **Kawahara S. (1998):** "[Chemotherapeutic agents under study]". *Nippon Rinsho*; 56 (12): 3096–9.
172. **Susan Blank, and Julia Schillinger (2009):** "DOHMH ALERT: Fluoroquinolone-resistant gonorrhea, NYC". USA: New York County Medical Society.
173. **Ortho-McNeil-Janssen Pharmaceuticals, Inc (2008):** "Floxin Tablets (Ofloxacin Tablets)".

174. **Rubinstein E. (2001):** "History of quinolones and their side effects". *Chemotherapy*; 47 (Suppl 3): 3–8; discussion 44–8.
175. **MacDougall C., Guglielmo BJ, Maselli J., and Gonzales R. (2005):** "Antimicrobial drug prescribing for pneumonia in ambulatory care". *Emerging Infect. Dis*; 11 (3): 380–4.
176. **Janssen Pharmaceutica (2008):** "HIGHLIGHTS OF PRESCRIBING INFORMATION".
177. **Fiscella RG, Lewis CC, and Jensen MK (2007):** "Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations". *Am J Health Syst Pharm*; 64 (19): 2069–73.
178. **http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1999/21085ltr.pdf.**
179. **Bayer Vital GmbH (2009):** "WICHTIGE INFORMATIONEN ÜBER EINSCHRÄNKUNG DER INDIKATIONEN UND NEUE SEHR SELTENE UNERWÜNSCHTE WIRKUNGEN" (in German) (PDF). Germany: akdae.
180. **http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21085S010_Avelox_Approv.pdf.**
181. **http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21085se1022,21277se1-017ltr.pdf.**
182. **http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021085s026,021277s022ltr.pdf.**
183. **http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021085s027,029,021277s024,025ltr.pdf**
184. **European Medicines Agency (2008):** "European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines" (PDF).
185. **USA: FDA. (2009):** "Center for drug evaluation and research Application number 21-598" (PDF).
186. **De Sarro A., and De Sarro G. (2001):** "Adverse reactions to fluoroquinolones. an overview on mechanistic aspects" (PDF). *Curr. Med. Chem*; 8 (4): 371–84.
187. **Nelson, Lewis H.; Flomenbaum, Neal; Goldfrank, et al. (2006):** Goldfrank's toxicologic emergencies. New York: McGraw-Hill, Medical Pub. Division.
188. **Taconelli, E.; De Angelis, G.; Cataldo, MA.; Pozzi, E.; Cauda, R. (2008):** "Does antibiotic exposure increase the risk of methicillin-resistant *Staphylococcus aureus* (MRSA) isolation? A systematic review and meta-analysis.". *J Antimicrob Chemother* ; 61 (1): 26–38.
189. **Carroll DN, and Carroll DG (2008):** "Interactions between warfarin and three commonly prescribed fluoroquinolones". *Ann Pharmacother*; 42 (5): 680–5.
190. **Nardiello S., Pizzella T., and Ariviello R. (2002):** "[Risks of antibacterial agents in pregnancy]". *Infez Med*; 10 (1): 8–15.
191. **Leibovitz E., Dror, and Yigal (2006):** "The use of fluoroquinolones in children.". *Curr Opin Pediatr*; 18 (1): 64–70.
192. **Scherer K., and Bircher AJ (2005):** "Hypersensitivity reactions to fluoroquinolones.". *Curr Allergy Asthma Rep*; 5 (1): 15–21.
193. **Medscape (2008):** "Fluoroquinolone Adverse Effects and Drug Interactions".
194. **The Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado (2009):** Fluoroquinolone Adverse Effects and Drug Interactions: Drug-Drug Interactions.

195. **Suling WJ, Seitz LE, Reynolds RC, and Barrow WW (2005):** "New Mycobacterium avium antifolate shows synergistic effect when used in combination with dihydropteroate synthase inhibitors". *Antimicrob. Agents Chemother*; 49 (11): 4801–3.
196. **CC Brackett, Singh H., and Block JH (2004):** "Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group". *Pharmacotherapy*; 24 (7): 856–70.
197. **Hawser S., Lociuro S., and Islam K. (2006):** "Dihydrofolate reductase inhibitors as antibacterial agents". *Biochem. Pharmacol*; 71 (7): 941–8.
198. **Coves J., Delon B., Climent I., Sjoberg BM, and Fontecave M. (1995):** "Enzymic and chemical reduction of the iron center of the Escherichia coli ribonucleotide reductase protein R2. The role of the C-terminus." *Eur J Biochem*; 233(1): 357-63.
199. **Heelon MW, and White M. (1998):** "Disulfiram-cotrimoxazole reaction". *J Pharmacotherapy*; 18 (4): 869.
200. **Brumfitt W., and Hamilton-Miller JM (1994):** "Limitations of and indications for the use of co-trimoxazole". *J Chemother*; 6 (1): 3–11.
201. **The Society for Healthcare Epidemiology of America and the Infectious Diseases (2010):** Society of America, guidelines for the management of Clostridium difficile infection, Infection Control and Hospital Epidemiology.
202. **Eisenstein, Barry I., Schaechter, and Moselio (2007):** "DNA and Chromosome Mechanics". In Schaechter, Moselio, Engleberg N. Cary, et al. Schaechter's mechanisms of microbial disease. Hagerstown, MD: Lippincott Williams & Wilkins; p. 28.
203. **Henry F. Chambers, and Daniel H. Deck (2009):** Miscellaneous antimicrobial agents. Disinfectants, Antiseptics, and Sterilants. In (Bertram G. Katzung. Basic and Clinical Pharmacology). 11ed. McGraw-Hill Medical; 8 (50): 884-892.
204. **Leclercq R., Bismuth R., Casin I., et al. (2000):** In Vitro Activity of Fusidic Acid Against Streptococci isolated from Skin and Soft Tissue Infections. *J. Antimicrob. Chemother*; 45(1): 27-29.
205. **The Guardian (2008):** Existing drug will cure hospital superbug MRSA, say scientists.
206. **Howden BP, and Grayson ML (2006):** "Dumb and dumber—the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus". *Clin Infect Dis*; 42 (3): 394–400.
207. **Castanheira M., Watters AA, Bell JM, Turnidge JD and Jones RN (2010):** Fusidic acid resistance rates and prevalence of resistance mechanisms among 'Staphylococcus spp. isolated in North America and Australia, 2007-2008. *Antimicrobial Agents and Chemotherapy*; 54:3614-3617.
208. **Fucidin patient information leaflet (2007):** archived by Government of Victoria, Australia.
209. **Henry F. Chambers, and Daniel H. Deck (2009):** Antimycobacterial drugs. In (Bertram G. Katzung. Basic and Clinical Pharmacology). 11ed.. McGraw-Hill Medical; 8 (47): 823-833.
210. **Susan B., Trevor, Anthony J., Katzung, and Bertram G. (2005):** Katzung & Trevor's pharmacology. New York: Lange Medical Books/McGraw Hill, Medical Pub. Division.
211. **Singh R, Manjunatha U, Boshoff HI, et al. (2008):** "PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release". *Science*; 322 (5906): 1392–5.

212. **Richard A. Harvey, and Pamela C. Champe (2008):** Pharmacology. Antimycobacterials. Lippincott's illustrated Reviews, 4th. Edition; 7 (34): 399-404.
213. **McIlleron H., Willemse M., Werely CJ, et al. (2009):** "Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines". Clinical Infectious Diseases; 48 (11): 1547–53.
214. **Alao AO, and Yolles JC (1998):** "Isoniazid-induced psychosis". The Annals of Pharmacotherapy; 32 (9): 889–91.
215. **Centers for Disease Control and Prevention (2000):** Core Curriculum on Tuberculosis. Division of Tuberculosis Elimination.
216. **Coulson, and Christopher J. (1994):** "Bacterial RNA-Polymerase - Rifampin as Antimycobacterial." Molecular Mechanisms of Drug Action. 2nd ed. Bristol, PA: Taylor Francis; pp. 40-41.
217. **American Thoracic Society, Centers for Disease Control, Infectious Diseases Society of America (2003):** "Treatment of Tuberculosis". Am J Respir Crit Care Med; 167 (602–662).
218. **Stockley, and Ivan H. (1994):** "Anticoagulant Drug Interactions." Drug Interactions. 3rd ed. Boston: Blackwell Scientific Publications; pp. 274-275.
219. **Riss J., Cloyd J., Gates J., and Collins S. (2008):** "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics." Acta Neurol Scand; 118 (2): 69–86.
220. **Zhang Y., and Mitchison D. (2003):** "The curious characteristics of pyrazinamide: a review". Int. J. Tuberc. Lung Dis; 7 (1): 6–21.
221. **Boshoff HI, Mizrahi V., and Barry CE (2002):** "Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I". Journal of Bacteriology; 184 (8): 2167–72
222. **Spaia S., Magoula I., Tsapas G., and Vayonas G. (2000):** "Effect of pyrazinamide and probenecid on peritoneal urate transport kinetics during continuous ambulatory peritoneal dialysis". Perit Dial Int; 20 (1): 47–52.
223. **Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., and Menzies D. (2003):** "Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis". Am J Resp Crit Care Med; 167 (11): 1472–7.
224. **Yendapally R., and Lee RE (2008):** "Design, synthesis, and evaluation of novel ethambutol analogues". Bioorg. Med. Chem; Lett. 18 (5): 1607–11.
225. **Lim SA (2006):** "Ethambutol-associated optic neuropathy". Ann. Acad. Med. Singap; 35 (4): 274–8.
226. **Mitchison DA (2000):** "Role of individual drugs in the chemotherapy of tuberculosis ". Int J Tuberc Lung Dis; 4 (9): 796–806.
227. **Daniel F., Seksik P., Cacheux W., Jian R., and Marteau P. (2004):** "Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis". Inflamm Bowel Dis; 10 (3): 258–260.
228. **Rieder HL, Arnadottir T., Trebucq A., and Enarson DA (2001):** "Tuberculosis treatment: dangerous regimens?". Int J Tuberc Lung Dis; 5 (1): 1–3.
229. **Nunn P., Porter J., and Winstanley P. (1993):** "Thiacetazone—avoid like poison or use with care?". Trans R Soc Trop Med Hyg; 87 (5): 578–82.
230. **Tunis SR, Hayward RS, Wilson MC et al. (1994):** Internists' attitudes about clinical practice guidelines. Ann Intern Med; 120: 956–63.

231. **World Health Report (2004):** Report of the World Health Organization Geneva, Switzerland.
232. **Guthrie R. (2001):** Community-acquired lower respiratory tract infections: etiology and treatment. *Chest*; 120(6):2021-34.
233. **Valcke Y., Pauwels R., van der Straeten M. (1990):** Pharmacokinetics of antibiotics in the lungs. *Eur Respir J*; 3: 715-722.
234. **Cazzola M., Matera MG, Polverino M., et al. (1995):** Pulmonary penetration of ceftazidime. *J Chemother*; 7: 50-54.
235. **Begg EJ, Robson RA, Saunders DA, et al. (2000):** The Pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. *Br J Clin Pharmacol*; 49: 32-38.
236. **Geller DE, Rosenfeld M., Waltz DA, and Wilmott RW (2003):** Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. *Chest*; 123: 28-36.
237. **Matera MG, Tufano MA, Polverino M., Rossi F., and Cazzola M. (1997):** Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. *Eur Respir J*; 10: 97-102.
238. **Marlin GE, Nicholls AJ, Funnell GR, Bradbury R. (1984):** Penetration of cefaclor into bronchial mucosa. *Thorax*; 39: 813-817.
239. **Krumpe P., and Radwanski E., et al. (1999):** The penetration of cefibuten into the respiratory tract. *Chest*; 116: 369-374.
240. **Mattie H., Hoogeterp JJ, Kaajan JPG, and Hermans J. (1987):** The penetration of erythromycin into human bronchial mucosa. *Br J Clin Pharmacol*; 24: 179-183.
241. **Khair OA, Andrews JM, Honeybourne D., et al. (2001):** Lung concentrations of telithromycin after oral dosing. *J Antimicrob Chemother*; 47:837-840.
242. **Andrews J., Honeybourne D., Jevons G., et al. (2003):** Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. *J Antimicrob Chemother*; 51: 727-730.
243. **Amsden GW (2001):** Advanced-generation macrolides: tissue-directed antibiotics. *Int J Antimicrob Agents*; 18: Suppl. 1, S11-S15.
244. **Gotfried MH, Danziger LH, and Rodvold KA (2001):** Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. *Chest*; 119: 1114-1122.
245. **Bergogne-Berezin E. (1992):** Pharmacokinetics of antibiotics into lower respiratory tract. Limits of bringing such an information. *Med Mal Infect*; 22, Special: 103-113.
246. **Rennard SI, Basset G., Lecossier D., et al. (1986):** Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. *J Appl Physiol*; 60: 532-538.
247. **Hand WL, Boozer RM, King-Thompson NL. (1985):** Antibiotic uptake by alveolar macrophages of smokers. *Antimicrob Agents Chemother*; 27: 42-45.
248. **Rodvold KA, Danziger LH, and Gotfried MH (2003):** Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. *Antimicrob Agents Chemother*; 47: 2450-2457.
249. **Tulkens PM (1991):** Intracellular distribution and activity of antibiotics. *Eur J Clin Microbiol Infect Dis*; 10: 100-106.

250. **Danesi R., Lupetti A., Barbara C., et al. (2003):** Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. *J Antimicrob Chemother*; 51: 939-945.
251. **Decre D., and Bergogne-Berezin E. (1993):** Pharmacokinetics of quinolones with special reference to the respiratory tract tree. An update. *J Antimicrob Chemother*; 31: 331-343.
252. **Bergogne-Berezin E. (1995):** New concepts in the pulmonary disposition of antibiotics. *Pulm Pharmacol*; 8: 65-81.
253. **Brigham KL, and Snapper JR (1988):** Lung lymph composition and flow in normal and abnormal states. In: Fishman AP, ed. *Pulmonary Diseases and Disorders*. New York, McGraw-Hill; pp. 909-918.
254. **Cazzolz M., Siniscalchi C., Vinciguerra A., et al. (1994):** Evaluation of lung tissue and hilar lymph node concentrations of azithromycin. *Int J Clin Pharmacol Ther Toxicol*; 32: 88-91.
255. **Mullar M. (2002):** Science, medicine, and the future: Microdialysis. *BMJ*; 165: 273-276.
256. **Herkner H., Muller MR, Kreischitz N., et al. (2002):** Closed chest microdialysis to measure antibiotic penetration into human lung tissue. *Am J Resp Crit Care Med*; 324: 588-591.
257. **Kimura M., Matsushima T., Nakamura J., and Kobashi Y. (1992):** Comparative study of penetration of lomefloxacin and ceftriaxone into transudative and exudative pleural effusion. *Antimicrob Agents Chemother*; 36: 2774-2777.
258. **Joseph J., Vaughan LM, and Basran GS. (1994):** Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid. *AnnPharmacother*; 28: 313-315.
259. **Cazzolz M., Matera MG, Terzano C., Balsi F., and Marsico SA. (2002):** Delivering antimicrobials to the lungs: concederations of optimising outcomes *Am J Respir Dis*; 1: 261-272.
260. **Cazzola M., Caputi M., Santangelo G., et al. (1997):** A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease. *J Chemother*; 9: 279-284.
261. **Wenzel RP, and Fowler AA (2006):** "Clinical practice. Acute bronchitis". *N. Engl. J. Med*; 355 (20): 2125–30.
262. **Smucny J BL, and Glazier R. (2006):** Beta2-agonists for acute bronchitis. *Cochrane Database of Systematic Reviews*; Issue 4.
263. **Fahey T SJ, Becker L., and Glazier R. (2004):** Antibiotics for acute bronchitis. *Cochrane Database of Systematic Reviews*; Issue 4.
264. **Shaker SB, Dirksen A., Bach KS, and Mortensen J. (2007):** "Imaging in chronic obstructive pulmonary disease". *COPD*; 4 (2): 143–61.
265. **Balter MS. (1994):** Recommendations on the management of chronic bronchitis. A practical guide for Canadian physicians. *Can Med Assoc J*; 151(suppl 10): 5-23.
266. **Blasi, and L. Allegra (2004):** Are antibiotics useful in AECP?. *Antibiotics and the Lung* ; 12: 189-197.
267. **The British Society for Antimicrobial Chemotherapy (2010):** Acute exacerbations of chronic bronchitis (AECB).

268. **Bach PB, Brown C., Gelfand SE, and McCrory DC (2001):** "Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence". *Ann. Intern. Med*; 134 (7): 600–20.
269. **Fiebach NH, and Barr RG (2007):** Respiratory tract infections. In NH Fiebach et al., eds., *Principles of Ambulatory Medicine*. Philadelphia: Lippincott Williams and Wilkins. 7th ed; pp. 474-500.
270. **World Health Organization (2008):** "Causes of death in neonates and children under five in the world (2004)".
271. **Hoare Z., and Lim WS (2006):** "Pneumonia: update on diagnosis and management". *BMJ*; 332 (7549): 1077–9.
272. **Dunn L. (2005):** "Pneumonia: classification, diagnosis and nursing management". *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*; 19 (42): 50-4.
273. **Loeb M. (2008):** Community-acquired pneumonia, search date June 2007. Online version of BMJ Clinical Evidence: <http://www.clinicalevidence.com>.
274. **Bartlett JG, Dowell SF, Mandell LA, et al. (2000):** Practice guidelines for the management of community-acquired pneumonia. *Clin Infect Dis*; 31:347-382.
275. **Mandell LA, Bartlett JG, Dowell SF, et al. (2003):** Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. *Clin Infect Dis*; 37:1405-1433.
276. **Mandell LA, Marrie TJ, Grossman RF, et al. (2000):** Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. *Clin Infect Dis*; 31:383-421.
277. **Falguera M., Sacristan O., Nogues A., et al. (2001):** Nonsevere community-acquired pneumonia: Correlation between cause and severity or comorbidity. *Arch Intern Med*; 161:1866-1872.
278. **Arancibia F., Bauer T., Ewig S., et al. (2002):** Community acquired pneumonia due to Gram-negative bacteria and *Pseudomonas aeruginosa*: Incidence, risk and prognosis. *Arch Intern Med*; 162:1849-1858.
279. **Dimopoulos G., Matthaiou DK, et al. (2008):** "Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis". *Drugs*; 68 (13): 1841–54.
280. **Marrie TJ, Lau CY, Wheeler SL, et al. (2000):** A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. *Community-Acquired Pneumonia. Intervention Trial Assessing Levofloxacin*. *JAMA*; 283:749-755.
281. **Chan SS, Yuen EH, Kew J., et al. (2001):** Community-acquired pneumonia. Implementation of a prediction rule to guide selection of patients for outpatient treatment. *Eur J Emerg Med*; 8:279-286.
282. **Fine MJ, Auble TE, Yealy DM, et al. (1997):** A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med*; 336:243–250.
283. **British Thoracic Society (2001):** Guidelines for the Management of Community Acquired Pneumonia in Adults. *Thorax*; 56(Suppl 4):IV1-IV64.
284. **Lim W., van der Eerden M., Laing R., et al. (2003):** Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. *Thorax*; 58:377-382.

285. **Mandell LA, Wunderink RG, Anzueto A., et al. (2007):** Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*; 44(Suppl 2):S27-S72.
286. **Menendez R., Ferrando D., Valles JM, and Vallterra J. (2002):** Influence of deviation from guidelines on the outcome of community-acquired pneumonia. *Chest*; 122:612-617.
287. **Thornsberry C., Sahm DF, Kelly LJ, et al. (2002):** Regional trends in antimicrobial resistance among clinical isolates of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* in the United States: Results from the TRUST Surveillance Program, 1999–2000. *Clin Infect Dis*; 34(Suppl 1):S4-S16.
288. **Heffelfinger JD, Dowell SF, Jorgensen JH, et al. (2000):** Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant *Streptococcus pneumoniae* Therapeutic Working Group. *Arch Intern Med*; 160:1399-1408.
289. **Niederman M., Mandell L., Anzueto A., et al. (2001):** Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med*; 163:1730-1754.
290. **Angus D., Marrie T., Obrosky D., et al. (2002):** Severe community-acquired pneumonia: Use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. *Am J Crit Care Med*; 166:717-723.
291. **Feldman RB, Rhew DC, Wong JY, et al. (2003):** Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: A 3½-year experience from a Veterans Affairs hospital. *Arch Intern Med*; 163:1718-1726.
292. **Heffelfinger JD, Dowell SF, Jorgensen JH, et al. (2000):** Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant *Streptococcus pneumoniae* Therapeutic Working Group. *Arch Intern Med* ; 160:1399-1408.
293. **Ho PL, Yung RW, Tsang DN, et al. (2001):** Increasing resistance of *Streptococcus pneumoniae* to fluoroquinolones: Results of a Hong Kong multicentre study in 2000. *J Antimicrob Chemother*; 48:659-665.
294. **Anderson KB, Tan JS, File Jr TM, et al. (2003):** Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. *Clin Infect Dis*; 37:376-381.
295. **Li JZ, Winston LG, Moore DH, and Bent S. (2007):** "Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis". *The American Journal of Medicine*; 120 (9): 783–90.
296. **Vardakas KZ, Siempos II, Grammatikos A., et al. (2008):** "Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials". *CMAJ*; 179 (12): 1269–77.
297. **Rhew DC, Goetz MB, and Shekelle PG (2001):** Evaluating quality indicators for patients with community-acquired pneumonia. *Jt Comm J Qual Improv*; 27:575-590.
298. **Siegel RE, Halpern NA, Almenoff PL, Lee A., Cashin R., and Greene JG. (1996):** A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. *Chest*;110: 965–971.

299. **Mandell LA (1994):** Antibiotics for pneumonia therapy. *Med Clin North Am*; 78: 997–1014.
300. **Schonwald S., Gunjaca M., Kolacny-Babic L., Car V., and Gosev M. (1990):** Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. *J Antimicrob Chemother*; 25(Suppl A): 123–126.
301. **Kinasewitz G., and Wood RG (1991):** Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. *Eur J Clin Microbiol Infect Dis*; 10:872–877.
302. **Halm EA, Fine MJ, Marrie TJ, et al. (1998):** Time to linical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. *JAMA*; 279: 1452–1457.
303. **Ramirez JA, and Bordon J. (2001):** Early switch from intravenous to oral antibiotics. in hospitalized patients with bacteremic *Streptococcus pneumoniae* community-acquired pneumonia. *Arch Intern Med*; 161: 848–850.
304. **Gerald L. Mandell, John E. Bennett, and Raphael Dolin (2004):** Mandell's Principles and Practices of Infection Diseases. 6th Edition.
305. **Ibrahim EH, Ward S., Sherman G., and Kollef MH (2000):** A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. *Chest*; 117:1434-1442.
306. **Antoni Torres, Rosario Menéndez, and Richard Wunderink (2010):** Pyogenic Bacterial Pneumonia and Lung Abscess. In (Robert J Mason, et al. Murray and Nadel's Textbook of Respiratory Medicine, 5th ed.) Vol 1, Part III, Section H;(32): 699-740.
307. **American Thoracic Society (1995):** Hospital-acquired pneumonia in adults: Diagnosis assessment of severity, initial antimicrobial therapy, and preventative strategies. *Am J Respir Crit Care Med*; 153:1711–1725.
308. **Weinstein RA (1991):** Epidemiology and control of nosocomial infections in adult intensive care units. *Am J Med*; 91 (suppl 3B): 1795.
309. **Furman CD, Rayner AV, and Tobin EP (2004):** "Pneumonia in older residents of long-term care facilities". *Am Fam Physician*; 70 (8): 1495–500.
310. **Loeb M. (2004):** "Pneumonia in the elderly". *Curr. Opin. Infect. Dis*; 17 (2): 127–30.
311. **Marrie TJ (2002):** Pneumonia in the long-term-care facility. *Infect Control Hosp Epidemiol*; 23:159-164.
312. **Depuydt P., and Vogelaers D. (2007):** "Nosocomial pneumonia outside the hospital: health-care associated pneumonia and nursing home pneumonia". (Dutch) , *Tijdschrift voor Geneeskunde (Belgium)*; 63 (5): 174–181.
313. **Mylotte JM (2006):** "Nursing home-acquired pneumonia: update on treatment options". *Drugs Aging*; 23 (5): 377–90.
314. **American Thoracic Society (2005):** Infectious Diseases Society of America. "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia". *Am. J. Respir. Crit. Care Med*; 171 (4): 388–416.
315. **Lorente L., Lecuona M., Jimenez A., Mora ML, and Sierra A. (2006):** "Ventilator-associated pneumonia using a heated humidifier or a heat and moisture exchanger: a randomized controlled trial"; *Crit Care* 10: 4.
316. **Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia (2005):** *Am J Respir Crit Care Med*; 171:388-416.

317. **Chastre J., and Fagon JY (2002):** Ventilator-associated pneumonia. *Am J Respir Crit Care Med*; 165:867-903.
318. **Combes A., Figliolini C., Trouillet JL, et al. (2002):** Incidence and outcome of polymicrobial ventilator-associated pneumonia. *Chest*; 121:1618-1623.
319. **Lorente L., Lecuona M., Jiménez A., Mora ML, and Sierra A. (2007):** "Influence of an endotracheal tube with polyurethane cuff and subglottic secretion drainage on pneumonia". *Am. J. Respir. Crit. Care Med*; 176 (11): 1079–83.
320. **Kollef MH, Afessa B., Anzueto A., et al. (2008):** "Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial". *JAMA*; 300 (7): 805–13.
321. **Grammatikos AP, Siempos, II, Michalopoulos A., and Falagas ME (2008):** Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. *Expert Rev Anti Infect Ther*; 6(6): 861-6.
322. **Niederman MS (2006):** "Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms". *Clin Infect Dis*; 42 Supp 2: S72–81.
323. **Kollef MH (2005):** "What is ventilator-associated pneumonia and why is it important?". *Respir Care*; 50: 714–21; discussion 721–4.
324. **Mukhopadhyay S., and Katzenstein AL (2007):** "Pulmonary disease due to aspiration of food and other particulate matter: a clinicopathologic study of 59 cases diagnosed on biopsy or resection specimens". *American Journal of Surgical Pathology*; 31 (5): 752–759.
325. **Lumpkin JR, and Westfall MD (1992):** Aspiration pneumonia. In: *Emergency Medicine: Concepts and Clinical Practice*; 1112-20.
326. **Van der Poll T., and Opal SM (2009):** Pathogenesis, treatment, and prevention of pneumococcal pneumonia. *Lancet*; 374:1543-1556.
327. **Whitney CG, Farley MM, Hadler J., et al. (2000):** Increasing prevalence of multidrug-resistant *Streptococcus pneumoniae* in the United States. *N Engl J Med*; 343:1917-1924.
328. **National Committee for Clinical Laboratory Standards (2002):** Twelfth Informational Supplement. M100-S12. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA, NCCLS.
329. **Sahm DF, Thornsberry C., Mayfield DC, et al. (2002):** In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of *Streptococcus pneumoniae*: MIC interpretation using NCCLS M100-S12 recommendations. *J Clin Microbiol*; 40:669-674.
330. **Von Gottberg A., Klugman KP, et al. (2008):** "Emergence of levofloxacin-non-susceptible *Streptococcus pneumoniae* and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study". *The Lancet*; 371: 1108.
331. **Vanderkooi OG, Low DE, Green K, et al. (2005):** Predicting antimicrobial resistance in invasive pneumococcal infections. *Clin Infect Dis*; 40:1288-1297.
332. **Martinez JA, Horcajada JP, Almela M., et al. (2003):** Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis*; 36: 389-395.

333. **Metersky ML, Ma A, Houck PM, and Bratzler DW (2007):** Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. *Chest*; 131: 466-473.
334. **Sniadack DH, Schwartz B., Lipman H., et al. (1995):** Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children implications for vaccine strategies. *Pediatric Infectious Disease Journal*; 14(6):503-510.
335. **Mayon-White R. (1989):** Protection for the asplenic patient. *Prescribers' J* 1994; 34: 165.
336. **Chattopadhyay B. (2004):** Splenectomy, pneumococcal vaccination and antibiotic prophylaxis. *Br J Hosp Med*; 41: 172.
337. **Muller MP, Low DE, Green KA, et al. (2003):** Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario, Canada. *Arch Intern Med*; 163:467-472.
338. **Farley MM (2001):** Group B streptococcal disease in nonpregnant adults. *Clin Infect Dis*; 33:556-561.
339. **Ahmed RA, Marrie TJ, and Huang JQ (2006):** Thoracic empyema in patients with community-acquired pneumonia. *Am J Med*; 119:877-883.
340. **Lin FY, Azimi PH, Weisman LE, et al. (2000):** Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995–1998. *Clin Infect Dis*; 31:76-79.
341. **Alos JI, Aracil B., Oteo J., and Gomez-Garces JL (2003):** Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) *Streptococcus pyogenes* in Spain. *J Antimicrob Chemother*; 51:333-337.
342. **Puri J., Talwar V., Juneja M., Agarwal KN, and Gupta HC (1999):** "Prevalence of anti-microbial resistance among respiratory isolates of *Haemophilus influenzae*". *Indian Pediatr*; 36 (10): 1029–32.
343. **Smith LG (2010):** *Mycoplasma pneumoniae* and its complications. *Infect Dis Clin North Am*; 24(1):57-60.
344. **Hyde TB, Gilbert M., Schwartz SB, et al. (2001):** Azithromycin prophylaxis during a hospital outbreak of *Mycoplasma pneumoniae pneumoniae*. *J Infect Dis*; 183:907-912.
345. **Wreghitt T. (1993):** Chlamydial infection of the respiratory tract. *Communicable Dis Rep*; 3: R119.
346. **Ridgway GL, Mumtaz G., and Fenelon L. (1991):** The invitro susceptibility of clarithromycin and other macrolides against the type strain of *Chlamydia pneumoniae* (TWAR). *J Antimicrob Chemother*; 27(Suppl A): 43.
347. **Grayston JT (1992):** Infections caused by *Chlamydia pneumoniae* strain TWAR. *Clin Infect Dis*; 15(5):757-61.
348. **Heuner K., and Swanson M. (2008):** *Legionella: Molecular Microbiology*. Caister Academic Press.
349. **Pedro-Botet ML, Stout JE, Yu VL (2002):** Legionnaires disease contracted from patient homes: The coming of the third plague?. *Eur J Clin Microbiol Infect Dis*; 21:699-705.
350. **Roig J., Carreres A., and Doming C. (1993):** Treatment of legionnaires' disease. Current recommendations. *Drugs*; 46: 63.
351. **El Ebiary M., Sarmiento X., Torres A., et al. (1997):** Prognostic factors of severe *Legionella pneumoniae* requiring admission to ICU. *Am J Respir Crit Care Med*; 156: 1467.

352. **El Solh A., Sikka P., Ramadan F., et al. (2001):** Etiology of severe pneumonia in the very elderly. *Am J Respir Crit Care Med*; 163:645-651.
353. **DeLeo FR, and Chambers HF (2009):** Reemergence of antibiotic-resistant *Staphylococcus aureus* in the genomics era. *J Clin Invest*; 119:2464-2474.
354. **Micek ST, Dunne M., and Kollef MH (2005):** Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant *Staphylococcus aureus*: Importance of treatment with antimicrobials inhibiting exotoxin production. *Chest*; 128:2732-2738.
355. **Stevens DL, Ma Y., Salmi DB, et al. (2007):** Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant *Staphylococcus aureus*. *J Infect Dis*; 195:202-211.
356. **Ryan KJ, and Ray CG (2004):** Sherris Medical Microbiology (4th ed.). McGraw Hill.
357. **Walsh NM, Casano AA, Manangan LP, et al. (2002):** Risk factors for *Burkholderia cepacia* complex colonization and infection among patients with cystic fibrosis. *J Pediatr*; 141:512-517.
358. **Balcht, Aldona & Smith, and Raymond (1994):** *Pseudomonas Aeruginosa*: Infections and Treatment. Informa Health Care; pp. 83–84.
359. **El Solh AA, and Alhajhusain A. (2009):** Update on the treatment of *Pseudomonas aeruginosa* pneumonia. *J Antimicrob Chemother*; 64:229-238
360. **Giamarellou H., and Antoniadou A. (2001):** Antipseudomonal antibiotics. *Med Clin North Am*; 85:19-42.v
361. **Valdezate S., Vindel A., Loza E., et al. (2001):** Antimicrobial susceptibilities of unique *Stenotrophomonas maltophilia* clinical strains. *Antimicrob Agents Chemother*; 45:1581-1584.
362. **Leung WS, Chu CM, Tsang KY, et al. (2006):** Fulminant community-acquired *Acinetobacter baumannii* pneumonia as a distinct clinical syndrome. *Chest*; 129 (1):102-109.
363. **Wisplinghoff H., Edmond MB, Pfaller MA, et al. (2000):** Nosocomial bloodstream infections caused by *Acinetobacter* species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. *Clin Infect Dis*; 31:690-697.
364. **Garnacho-Montero J., Ortiz-Leyba C., et al. (2005):** *Acinetobacter baumannii* ventilator-associated pneumonia: Epidemiological and clinical findings. *Intensive Care Med*; 31:649-655.
365. **Urban C., Segal-Maurer S., and Rahal JJ (2003):** Considerations in control and treatment of nosocomial infections due to multidrug-resistant *Acinetobacter baumannii*. *Clin Infect Dis*; 36:1268-1274.
366. **Maskell NA, Batt S., Hedley EL, et al. (2006):** The bacteriology of pleural infection by genetic and standard methods and its mortality significance. *Am J Respir Crit Care Med*; 174:817-823.
367. **Raoult D., Tissot-Dupont H., Foucault C., et al. (2000):** Q fever 1985–1998. Clinical and epidemiologic features of 1,383 infections. *Medicine (Baltimore)*; 79:109-123.
368. **Marrie TJ, and Raoult D. (2002):** Update on Q fever, including Q fever endocarditis. *Curr Clin Top Infect Dis*; 22:97-124.
369. **Torres HA, Reddy BT, Raad II, et al. (2002):** Nocardiosis in cancer patients. *Medicine (Baltimore)*; 81:388-397.

370. **Brown-Elliott BA, Ward SC, Crist CJ, et al. (2001):** In vitro activities of linezolid against multiple *Nocardia* species. *Antimicrob Agents Chemother*; 45:1295-1297.
371. **Bush LM, Abrams BH, Beall A., and Johnson CC (2001):** Index case of fatal inhalational anthrax due to bioterrorism in the United States. *N Engl J Med*; 345:1607-1610.
372. **Bartlett JG, Inglesby Jr TV, and Borio L. (2002):** Management of anthrax. *Clin Infect Dis*; 35:851-858.
373. **Inglesby TV, OToole T, Henderson DA, et al. (2002):** Anthrax as a biological weapon, 2002: Updated recommendations for management. *JAMA*; 287:2236-2252.
374. **MMWR Morb Mortal Wkly Rep (2003):** Imported plague—New York City, 2002; 52:725-728.
375. **Inglesby TV, Dennis DT, Henderson DA, et al. (2000):** Plague as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. *JAMA*; 283:2281-2290.
376. **Mwenge W., Butler T., Mgema S., et al. (2006):** Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. *Clin Infect Dis*; 42:614-621.
377. **Currie BJ, Fisher DA, Howard DM, et al. (2000):** Endemic melioidosis in tropical northern Australia: A 10-year prospective study and review of the literature. *Clin Infect Dis*; 31:981-986.
378. **White NJ (2003):** Melioidosis. *Lancet*; 361:1715-1722.
379. **Dennis DT, Inglesby TV, Henderson DA, et al. (2001):** Tularemia as a biological weapon: Medical and public health management. *JAMA*; 285:2763-2773.
380. **Kedlaya I., Ing MB, and Wong SS (2001):** *Rhodococcus equi* infections in immunocompetent hosts: Case report and review. *Clin Infect Dis*; 32:E39-E46.
381. **Rosenstein NE, Perkins BA, Stephens DS, et al. (2001):** Meningococcal disease. *N Engl J Med*; 344:1378-1388.
382. **Peglow SL, Smulian AG, Linke MJ et al. (1990):** Serologic responses to *Pneumocystis carinii* antigens in health and disease. *J Infect Dis*; 161: 296.
383. **Lundgren B., Lundgren JD, Nielsen T., et al. (1993):** Antibody response to a major human *Pneumocystis carinii* surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia. *Eur J Clin Microbiol Infect Dis*; 12: 105.
384. **Morris-Jones SD, and Easterbrook PJ. (1997):** Current issues in the treatment and prophylaxis of *Pneumocystis carinii* pneumonia. *J Antimicrob Chemother*; 40: 315.
385. **Santamauro JT, and Stover DE. (1997):** *Pneumocystis carinii* pneumonia. *Med Clin North Am*; 81: 229.
386. **Safrin S., Finkelstein DM, Dumont M., et al. (1996):** Comparison of three regimens for treatment of mild to moderate *Pneumocystis carinii* pneumonia in patients with AIDS. *Ann Intern Med*; 124: 792.
387. **Held M., and Goebel F-D. (1996):** Primary and secondary prophylaxis for *Pneumocystis carinii* related complications in HIV patients. *Eur Respir J*; 9: 868.
388. **Centers for Disease Control (1997):** USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. *Ann Intern Med*; 127: 922.
389. **Medscape (2007):** "Pneumonia and Other Pulmonary Infections: Lung Abscess".

390. **Bartlett JG (2005):** "The role of anaerobic bacteria in lung abscess". *Clin. Infect. Dis*; 40 (7): 923–5
391. **Hirshberg B., Sklair-Levi M., Nir-Paz R., et al. (1999):** "Factors predicting mortality of patients with lung abscess". *Chest*; 115 (3): 746–50.
392. **Moreira Jda S., Camargo Jde J., et al. (2006):** "Lung abscess: analysis of 252 consecutive cases diagnosed between 1968 and 2004". *Jornal brasileiro de pneumologia : publicação oficial da Sociedade Brasileira de Pneumologia e Tisiologia*; 32 (2): 136–4.
393. **Bartlett JG (1991):** Antibiotics in lung abscess. *Semin Respir Infect*; 6(2):103-11.
394. **Peters G., and Becker K. (1996):** Epidemiology, control and treatment of methicillin-resistant *Staphylococcus aureus* infection. *Drugs*; 52 (suppl 2):50.
395. **Bryant RE, and Salmon CJ (1996):** Pleural empyema. *Clin Infect Dis*; 22(5):747-62; quiz 763-4.
396. **Hughes CE, and Van Scoy RE (1991):** Division of Infectious Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905. *Semin Respir Infect*; 6 (2): 94-102.
397. **LeMense GP, Strange C., and Sahn SA (1995):** Empyema thoracis. Therapeutic management and outcome. *Chest*; 107(6):1532-7.
398. **Hassan, and Isaac (2007):** "Bronchiectasis". *eMedicine Specialties Encyclopedia*. Gibraltar: WebMD.
399. **Yalçın E., Kiper N., Özcelik U., Doğru D., Fırat P., and Şahin A. (2006):** Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. *J Clin Pharm Ther*; 31(1):49-55.
400. **Evans DJ, Bara AI, and Greenstone M. (2003):** Prolonged antibiotics for purulent bronchiectasis. *Cochrane Database Syst Rev*; (4):CD001392.
401. **Evans DJ, and Greenstone M. (2006):** Long-term antibiotics in the management of non-CF bronchiectasis--do they improve outcome?. *Respir Med*; 97(7):851-8.
402. **Rubin BK. (2008):** Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. *J Aerosol Med Pulm Drug Deliv*; 21(1):71-6.
403. **Scheinberg P., and Shore E. (2005):** A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. *Chest*; 127(4):1420-6.
404. **Kliegman Robert, and Richard M. Kliegman (2006):** *Nelson essentials of pediatrics*. St. Louis, Mo: Elsevier Saunders.
405. **Pai VB, and Nahata MC (2001):** "Efficacy and safety of aerosolized tobramycin in cystic fibrosis". *Pediatr. Pulmonol*; 32 (4): 314–27.
406. **Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, and Heijerman HG (2004):** "Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study". *J. Cyst. Fibros*; 3 (1): 23–8.
407. **McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, and Montgomery AB (2008):** "Inhaled aztreonam lysine for chronic airway *Pseudomonas aeruginosa* in cystic fibrosis". *Am. J. Respir. Crit. Care Med*; 178 (9): 921–8.
408. **Hansen CR, Pressler T., Koch C., and Høiby N. (2005):** "Long-term azitromycin treatment of cystic fibrosis patients with chronic *Pseudomonas aeruginosa* infection; an observational cohort study". *J. Cyst. Fibros*; 4 (1): 35–40.
409. **Tan KH, Mulheran M., Knox AJ, and Smyth AR (2003):** "Aminoglycoside prescribing and surveillance in cystic fibrosis". *Am. J. Respir. Crit. Care Med*; 167 (6): 819–23.

410. **Kumar Vinay, Abbas Abul K., Fausto Nelson, and Mitchell Richard N. (2007):** Robbins Basic Pathology (8th ed.). Saunders Elsevier; pp. 516–522.
411. **Brennan PJ, and Nikaido H. (1995):** "The envelope of mycobacteria". *Annu. Rev. Biochem*; 64: 29–63.
412. **Centers for Disease Control and Prevention (CDC), Division of Tuberculosis Elimination (2003):** Core Curriculum on Tuberculosis: What the Clinician Should Know. 4th edition.
413. **O'Brien R. (1994):** "Drug-resistant tuberculosis: etiology, management and prevention". *Semin Respir Infect*; 9 (2): 104–12.
414. **Blumberg HM, Burman WJ, Chaisson RE, et al. (2003):** for the American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. *Am J Respir Crit Care Med*; 167:603-662.
415. **Wang JY, Hsueh PR, Jan IS, et al. (2006):** "Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas". *Thorax*; 61 (10): 903–8.
416. **GreenFacts Website (2009):** "Scientific Facts on Drug-resistant Tuberculosis".
417. **Cornwall, and Janet (1997):** "Tuberculosis: A Clinical Problem of International Importance." *The Lancet*; 660.
418. **British thoracic society (1994):** "A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society". *British Journal of Diseases of the Chest*; 78 (4): 330–6.
419. **Ormerod LP, and Horsfield N. (1987):** "Short-course antituberculous chemotherapy for pulmonary and pleural disease: 5 years' experience in clinical practice". *British Journal of Diseases of the Chest*; 81 (3): 268–71.
420. **Elzinga G., Raviglione MC, and Maher D. (2004):** "Scale up: meeting targets in global tuberculosis control". *Lancet*; 363 (9411): 814–9.
421. **Cohn DL, Catlin BJ, Peterson KL, et al. (1990):** "A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen". *Annals of Internal Medicine* 112 (6): 407–15.
422. **Iseman MD (1998):** "MDR-TB and the developing world--a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy". *The International Journal of Tuberculosis and Lung Disease*; 2 (11): 867.
423. **Sterling TR, Lehmann HP, and Frieden TR (2003):** "Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis". *BMJ*; 326 (7389): 574.
424. **Sumartajo E. (1993):** When tuberculosis treatment fails. Asocial behavioural account of patient adherence. *Am Rev Respir Dis*; 147- 1311.
425. **Schluger N., Ciotoli C., Cohen D., Johnson H., and Rom WN (1995):** Comprehensive tuberculosis control for patients at high risk for noncompliance. *Am J Respir Crit Care Med*; 151:1486.
426. **Zent C., and Smith P. (1995):** "Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide". *Tubercle and Lung Disease*; 76 (2): 109–13.
427. **Grange JM, and Festenstein F. (1993):** The human dimension of tuberculosis control. *Tubercle Lung Dis*; 74: 219.

428. **Schraufuagel D., Stoner R., Whiting E., Snukst-Torbeck G., and Werhane MJ. (1990):** Testing for isoniazid. An evaluation of the Arkansas method. *Chest*; 98: 314.
429. **Gangadharam PRJ (1994):** Chemotherapy of tuberculosis under program conditions. With special relevance to India. *Tubercle Lung Dis*; 75: 241.
430. **Hong Kong Chest Service Tuberculosis Research Centre, British Medical Research Council (1998):** "A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: results at 5 years". *Am Rev Respir Dis*; 139: 871–76.
431. **O’Riordan P., Schwab U., Logan S., et al. (2008):** "Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multidrug-resistant tuberculosis: case control study". *PLoS ONE*; 3 (9): e3173.
432. **Forget EJ, and Menzies D. (2006):** "Adverse reactions to first-line antituberculosis drugs". *Expert Opinion on Drug Safety*; 5 (2): 231–49.
433. **Blumberg HM, Burman WJ, Chaisson RE, et al. (2003):** for the American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. *Am J Respir Crit Care Med*; 167:603-662.
434. **World Health Organization (2003):** Treatment of Tuberculosis: Guidelines for National Programmes. 3rd ed. Geneva, World Health Organization; pp 1–108.
435. **Drobac PC, et al. (2005):** "Treatment of Multidrug-Resistant Tuberculosis during Pregnancy: Long-Term Follow-Up of 6 Children with Intrauterine Exposure to Second-Line Agents". *Clin Infect Dis*; 40 (11): 1689–92.
436. **Palacios E., Dallman R., Muñoz M., et al. (2009):** "Drug-resistant tuberculosis and pregnancy: Treatment outcomes of 38 cases in Lima, Peru". *Clin Infect Dis*; 48 (10): 1413–1419.
437. **Ormerod LP, and Horsfield N. (1996):** "Frequency and type of reactions to antituberculosis drugs: observations in routine treatment". *Tubercle and Lung Disease*; 77 (1): 37–42.
438. **William N. Rom, and Stuart Garay (1996):** Tuberculosis. Core Curriculum On Tuberculosis. Center for disease control and prevention (CDC).
439. **Hammer SM, Turmen T., Varelzdis B., et al. (2002):** Antiretroviral guidelines for resource-limited settings: The WHO's public health approach. *Nat Med*; 8:649-650.
440. **Vernon A, Burman W, Benator D, et al. (1999):** Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. *Lancet*; 353:1843-1847.
441. **MMWR Morb Mortal Wkly (2002):** Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. *Rep*; 51:214-215.
442. **Kang’ombe CT, Harries AD, Ito K, et al. (2004):** Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: Mortality at 7 years according to initial HIV status and type of TB. *Int J Tuberc Lung Dis*; 8:829-836.
443. **Leung CC, Lam TH, et al. (2008):** Diabetic control and risk of tuberculosis: a cohort study. *Am J Epidemiol*; 167: 1486–1494.
444. **World Health Organization (2008):** Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update. Geneva, World Health Organization; pp 50–271.

445. **Iseman, and Michael D. (1993):** "Treatment of multidrug-resistant tuberculosis". *N Engl J Med*; 329 (11): 784–791.
446. **Francis J. (2008):** Curry National Tuberculosis Center and California Department of Public Health: Treatment. In: Francis J, ed. *Drug-Resistant Tuberculosis: A Survival Guide for Clinicians*, Curry National Tuberculosis Center; 32-56.
447. **Mitnick C., et al. (2003):** "Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru". *N Eng J Med*; 348 (2): 119–128.
448. **Leimane V., et al. (2005):** "Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study". *Lancet*; 365 (9456): 318–26.
449. **Orenstein EW, Basu S., Shah NS, et al. (2009):** "Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis". *Lancet Infect Dis*; 9 (3): 153–161.
450. **MMWR Morb Mortal Wkly (2006):** Emergence of *Mycobacterium tuberculosis* with extensive resistance to second-line drugs—worldwide, 2000–2004. Rep; 55:301-305.
451. **Gandhi NR, Moll A., Sturm AW, et al. (2006):** Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet*; 368:1575-1580.
452. **Center for Disease Control (2006):** "Emergence of *Mycobacterium tuberculosis* with Extensive Resistance to Second-Line Drugs — Worldwide, 2000–2004". *MMWR Weekly*; 55 (11): 301–305.
453. **Tam Cheuk-Ming, Yew Wing-Wai, and Yuen Kwok-Yung (2009):** "Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects". *Expert Review of Clinical Pharmacology*; 2: 405–421.
454. **Mitnick CD, Shin SS, Seung KJ, et al. (2008):** Comprehensive treatment of extensively drug-resistant tuberculosis. *N Engl J Med*; 359:563-574.
455. **Farmer P. (2001):** "The major infectious diseases in the world--to treat or not to treat?". *N. Engl. J. Med*; 345 (3): 208–10.
456. **Steering Group, and Ernesto Jaramillo (2008):** Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva, Switzerland: World Health Organization; pp. 51.
457. **Hong Kong Chest Service, Medical Research Council (1981):** "Controlled trial of four thrice weekly regimens and a daily regimen given for 6 months for pulmonary tuberculosis". *Lancet*; 1 (8213): 171–4.
458. **Harries AD, Hargreaves NJ, Kumwenda J, Kwanjana1 JH, and Salaniponi1 FM (2000):** "Trials of anti-tuberculosis treatment in areas of high human immunodeficiency virus prevalence in sub-Saharan Africa". *Int J Tuberc Lung Dis*; 4 (11): 998–1001.
459. **Fourie B., and Weyer K. (2000):** "Trials of anti-tuberculosis treatment as a diagnostic tool in smear-negative tuberculosis are of questionable benefit". *Int J Tuberc Lung Dis*; 4 (11): 997.
460. **Farer LS. (1998):** Chemoprophylaxis. *Am Rev Respir Dis*; 125: 102.
461. **A. M. Emmerson. (2000):** *Mycobacterial disease*. In (Antimicrobial Chemotherapy, 4th Edition). Part V, The therapeutic use of antimicrobial agents; (26): 287-300.
462. **Henry F. Chambers, and Daniel H. Deck. (2009):** Antimycobacterial drugs. 11ed. McGraw-Hill Medical. In (Bertram G. Katzung. *Basic and Clinical Pharmacology*); 8 (47): 823-833.